三力制药：2亿元引进阿尔茨海默病新药

Core Viewpoint - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University for the HXW2324 compound and related patent application rights, aiming to enhance its innovative drug product portfolio through collaboration with academic research [1] Group 1: Contract Details - The total transfer price for the HXW2324 compound is 200 million RMB, which includes a milestone payment of 20 million RMB and a sales commission of 180 million RMB [1] - The contract is designed to integrate the company's industrialization capabilities with university research resources to promote the transformation of innovative drug research results [1] Group 2: Product Information - The HXW2324 compound is a preclinical candidate for developing new treatments for Alzheimer's disease (AD) [1]